AmerisourceBergen launched Clinical Trial Navigator, a solution suite that supports biopharmaceutical clinical trial recruitment within community-based specialty practices.
Fox Chase Cancer Center used to be a place where Nobel laureates toiled. Now, people who love the place—and in oncology, many people do—are hoping that Jonathan Chernoff, Fox Chase’s new director, will restore vitality to the venerable Philadelphia-based cancer center.
Hospitals and radiology clinics are rationing—of all things—intravenous contrast agents used for computed tomography imaging.
The Union for International Cancer Control and multiple partners are establishing the Access to Oncology Medicines Coalition, a global partnership to increase access to quality-assured essential cancer medicines in low- and lower-middle-income countries, and to help countries develop the capacity for their proper use.
The Committee on Energy and Commerce passed a bill May 18 that would authorize the establishment of the Advanced Research Project Agency for Health as an independent agency within HHS.
ASCO and the Association of Community Cancer Centers jointly released recommendations addressing the lack of equity, diversity, and inclusion in cancer clinical trials.
Vetta Sanders Thompson was named the inaugural associate director of diversity, equity, and inclusion at Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital.
The Oversight Committee of the Cancer Prevention and Research Institute of Texas approved a slate of 17 recruitment awards for a total of almost $48 million.
Ryan Schoenfeld was named chief executive officer of The Mark Foundation for Cancer Research. Schoenfeld will oversee the foundation’s scientific programs, investments, and operations, and will be responsible for shaping how The Mark Foundation allocates the $500 million in additional funding recently committed by its founder (The Cancer Letter, Feb. 18, 2022).
The Pancreatic Cancer Action Network awarded the first PanCAN Therapeutic Accelerator Award to Verastem Oncology to evaluate their investigational treatments, VS-6766 and defactinib, in an early-stage (phase Ib/II) pancreatic ductal adenocarcinoma clinical trial.
